These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30401573)

  • 1. Efficacy and safety of drug-eluting stent for the intracranial atherosclerotic disease: A systematic review and meta-analysis.
    Ye G; Yin X; Yang X; Wang J; Qi P; Lu J; Wang L; Wang D
    J Clin Neurosci; 2019 Jan; 59():112-118. PubMed ID: 30401573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Drug-Eluting Stent With Bare-Metal Stent in Patients With Symptomatic High-grade Intracranial Atherosclerotic Stenosis: A Randomized Clinical Trial.
    Jia B; Zhang X; Ma N; Mo D; Gao F; Sun X; Song L; Liu L; Deng Y; Xu X; Zhang Y; Liu Z; Guan S; Zhang F; Li B; Zheng H; Liu X; Liu Y; Chen K; Shuai J; Wan J; Wang J; Shi X; Li T; Chang B; Liebeskind DS; Yu W; Miao Z;
    JAMA Neurol; 2022 Feb; 79(2):176-184. PubMed ID: 34982098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endovascular treatment for symptomatic intracranial artery stenosis: protocol for a systematic review and network meta-analysis.
    Wang T; Wang X; Yang K; Zhang J; Luo J; Gao P; Ma Y; Jiao L; Ling F
    BMJ Open; 2018 Jul; 8(7):e022359. PubMed ID: 29991634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a Drug-Eluting Stent vs. Bare Metal Stent for the Treatment of Symptomatic Intracranial and Vertebral Artery Stenosis.
    Si JH; Ma N; Gao F; Mo DP; Luo G; Miao ZR
    Front Neurol; 2022; 13():854226. PubMed ID: 35911924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of stent versus medical therapy for symptomatic patients with intracranial atherosclerotic stenosis: A meta-analysis.
    Zhang Q; Dong K; Song H
    J Neurol Sci; 2017 Jan; 372():272-278. PubMed ID: 28017227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and Risk Factors of In-Stent Restenosis for Symptomatic Intracranial Atherosclerotic Stenosis: A Systematic Review and Meta-Analysis.
    Peng G; Zhang Y; Miao Z
    AJNR Am J Neuroradiol; 2020 Aug; 41(8):1447-1452. PubMed ID: 32732271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial experience with an everolimus-eluting, second-generation drug-eluting stent for treatment of intracranial atherosclerosis.
    Natarajan SK; Ogilvy CS; Hopkins LN; Siddiqui AH; Levy EI
    J Neurointerv Surg; 2010 Jun; 2(2):104-9. PubMed ID: 21990588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.
    Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G;
    EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-eluting stent for the treatment of symptomatic vertebral origin stenosis: Long-term results.
    Chen X; Huang Q; Hong B; Zhang Y; Xu Y; Liu J
    J Clin Neurosci; 2011 Jan; 18(1):47-51. PubMed ID: 20888236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Wingspan Stenting for Severe Symptomatic Atherosclerotic Stenosis of the Middle Cerebral Artery: Analysis of 278 Continuous Cases.
    Zhao T; Zhu WY; Xiong XY; Li J; Wang L; Ding HY; Wei F; Zhou Y; Gong ZL; Cheng SY; Liu Y; Shuai J; Yang QW
    J Stroke Cerebrovasc Dis; 2016 Oct; 25(10):2368-72. PubMed ID: 27324301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracranial Angioplasty with Enterprise Stent for Intracranial Atherosclerotic Stenosis: A Single-Center Experience and a Systematic Review.
    Sun B; Xu C; Wu P; Li M; Xu S; Wang C; Liu X; Ling Y; Shi H
    Biomed Res Int; 2021; 2021():6645500. PubMed ID: 33959660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant Asymptomatic Intracranial Atherosclerotic Stenosis Increase the 30-Day Risk of Stroke in Patients Undergoing Symptomatic Intracranial Atherosclerotic Stenosis Stenting.
    Zhao J; Li X; Chi LX; Ma BW; Du YH; Chen GS; Zhou HD; Li JC; Jiang XJ; Yang QW; Zhao XF; Yao XF
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):479-485. PubMed ID: 29056405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial Experience With the Next-Generation Resolute Onyx Zotarolimus-Eluting Stent in Symptomatic Intracranial Atherosclerotic Disease.
    Hassan AE; Mohammaden MH; Rabah RR; Tekle WG
    Front Neurol; 2020; 11():570100. PubMed ID: 33101179
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term outcome of drug-eluting stenting for stenoses of the intracranial vertebrobasilar artery and vertebral ostium.
    Lu H; Zheng P; Zhang W
    J Neurointerv Surg; 2013 Sep; 5(5):435-9. PubMed ID: 22738774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis.
    Zhao L; Zhu W; Zhang X; He D; Guo C
    BMC Cardiovasc Disord; 2017 Jan; 17(1):16. PubMed ID: 28061808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wingspan stenting for intracranial atherosclerotic stenosis: clinical outcomes and risk factors for in-stent restenosis.
    Shin YS; Kim BM; Suh SH; Jeon P; Kim DJ; Kim DI; Kim BS; Kim KH; Heo JH; Nam HS; Kim YD
    Neurosurgery; 2013 Apr; 72(4):596-604; discussion 604. PubMed ID: 23277374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Characteristics of In-Stent Restenosis After Drug-Eluting Stent Implantation in Femoropopliteal Lesions and 1-Year Prognosis After Repeat Endovascular Therapy for These Lesions.
    Iida O; Takahara M; Soga Y; Hirano K; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
    JACC Cardiovasc Interv; 2016 Apr; 9(8):828-834. PubMed ID: 27101908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: Patient-level pooled analysis of Korean Multicenter in-Stent Restenosis Registry.
    Lee JM; Rhee TM; Hahn JY; Hwang D; Park J; Park KW; Kim HL; Kim SH; Chae IH; Doh JH; Jeon KH; Choi YJ; Park JS; Choi SH; Gwon HC; Koo BK; Alfonso F; Kim HS
    Int J Cardiol; 2017 Mar; 230():181-190. PubMed ID: 28043660
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.